FDA to review possible heart risks with AstraZeneca’s diabetes drug

[Reuters – UK Focus] – The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc (NYSE: AZN – news) ‘s widely-used diabetes drug saxagliptin, marketed as Onglyza and Kombiglyze XR. The health regulator more

View todays social media effects on AZN

View the latest stocks trending across Twitter. Click to view dashboard

See who Astrazeneca is hiring next, click here to view